Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smile Train And BioDigital Introduce App To Train Surgeons In Cleft Palate Repair

Executive Summary

Smile Train introduces a new mobile app to accelerate much-needed virtual surgical training for cleft-lip and palate repair.

You may also be interested in...



Expert Panel Says Interoperability Remains Barrier In Digital Surgery Transformation

An expert panel foresees increased adoption of digital tools in the OR, not just robotics. These tools help surgeons make more informed decisions and improve outcomes, but barriers remain.

Lilly Signs Deals With Dexcom, Glooko, myDiabby, Roche For Diabetes Management Solutions

Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.

BD Plans To Spin Off Diabetes Care Business

BD believes the independent new company will create shareholder value and is part of the BD 2025 growth strategy. 

Topics

UsernamePublicRestriction

Register

MT143840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel